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Abstract
To investigate the interrelation between economic, marital, and known histo-
pathologic/therapeutic prognostic factors in presentation and survival of patients 
with lung cancer in nine different ethnic groups. A retrospective review of the 
SEER database was conducted through the years 2007–2012. Population differ-
ences were assessed via chi- square testing. Multivariable analyses (MVA) were 
used to detect overall survival (OS) differences in the total population (TP, 
N = 153,027) and for those patients presenting with Stage IV (N = 70,968). 
Compared to Whites, Blacks were more likely to present with younger age, 
male sex, lower income, no insurance, single/widowed partnership, less squamous 
cell carcinomas, and advanced stage; and experience less definitive surgery, lower 
OS, and lung cancer- specific (LCSS) survival. White Hispanics presented with 
younger age, higher income, lower rates of insurance, single/widowed partner-
ship status, advanced stage, more adenocarcinomas, and lower rates of definitive 
surgery, but no difference in OS and LCSS than Whites. In the TP and Stage 
IV populations, MVAs revealed that OS was better or equivalent to Whites for 
all other ethnic groups and was positively associated with insurance, marriage, 
and higher income. Blacks presented with more advanced disease and were 
more likely to succumb to lung cancer, but when adjusted for prognostic fac-
tors, they had a better OS in the TP compared to Whites. Disparities in income, 
marital status, and insurance rather than race affect OS of patients with lung 
cancer. Because of their presentation with advanced disease, Black and Hispanics 
are likely to have increased benefit from lung cancer screening.
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Introduction
In the United States, lung cancer occurs in approximately 
225,000 patients and is associated with over 160,000 deaths 
annually [1]. However, despite the prevalence of this 
malignancy, the influence and/or interrelation between 
economic and insurance factors as well as ethnicity have 
been poorly studied. One recent study did investigate 
racial/ethnic differences in lung cancer incidence and 
mortality in women, but found no differences in fully 
adjusted models [2]. Additionally, another report dem-
onstrated lung cancer rates have dropped faster in Black 
women than the rates in Whites since the 1990s [3]. 
Using the Christiana Care Tumor Registry (CCTR) in 
Delaware, disparities in survival were related to lower 
socioeconomic status and having Medicaid insurance, but 
there were no such differences related to race or sex [4]. 
A National Cancer Database project [5] found income 
and race (White, Black, and Asian) were not related to 
survival, but patients with Medicaid or who were unin-
sured had worse outcomes [5].
The purpose of our analysis was to study whether marital 
status, household income, insurance type, and ethnicity 
play a role in the presentation and prognosis of all patients 
with NSCLC and those presenting with metastatic disease 
in the United States. We feel this investigation is unique 
because we investigate the racial groups in terms of their 
presenting economic, histopathologic, and marital status 
and assess whether racial differences account for differing 
prognoses.
Materials­and­Methods
Data­source/cohort­selection
The “SEER- 18” database was available since the year 2000 
[6] and covers approximately 28% of the American popu-
lation [6]. The years 2007–2012 were queried to identify 
patients with microscopically confirmed NSCLC as their 
first primary tumor.
Outcome and presenting characteristics were examined 
for all patients (153,027) and patients with metastatic 
disease (70,968) for whom sufficient information was col-
lected to assess the outcomes in relation to patient, eco-
nomic, histopathologic, and insurance variables.
Outcome­variables­and­other­covariates
The main purpose of our analysis was to examine whether 
there were differences in presenting characteristics and 
outcome in nine different ethnic groups by examining 
marital status, household income, and insurance type in 
addition to established histopathologic (tumor location, size, 
differentiation, stage, and histology), treatment factors 
(radiation and definitive surgical procedure), and patients 
factors (age, gender, marital status, presenting year, and 
SEER registry site). The patients with lung cancer were 
split into nine different ethnic groups as follows: White 
non- Hispanic (White), Black, White Hispanic (Hispanic), 
American Indian/Alaskan native (AI/AN), Chinese, Japanese, 
South Asian (Asian Indian and Pakistani), other Asians 
(OA, Filipino, Thai, Vietnamese, Korean, Kampuchean, 
Laotian, and Hmong), and other races (OR, Chamorran, 
Fiji Islander, Guamanian, Hawaiian, Melanesian, 
Micronesian, New Guinean, Pacific Islander, Polynesian, 
Samoan, Tahitian, Tongan, unknown, and others) in both 
the TP and Stage IV populations. The number of Black 
Hispanic patients was scant in both the TP (1.0%) and 
the Stage IV groups (0.7%), thus precluding the possibility 
of considering a separate patient category, and thus, Black 
Hispanic patients are included in the Black category, similar 
to a past study [7]. Throughout this manuscript, the term 
population(s) will refer to total population of patients with 
lung cancer and those with Stage IV disease, while group(s) 
will refer to the nine different ethnicities.
At the time of our analysis, SEER did not contain 
information regarding whether systemic therapy was given, 
nor does SEER contain information regarding the systemic 
agents that were used. SEER does contain information 
including the following: year of diagnosis (1975–2014), 
sex, patient age (1–84 and 85+), SEER registry location, 
median household income, insurance, marital status, origin 
recode (Hispanic, non- Hispanic), race/ethnicity, tumor 
location, primary site, sequence number, grade, laterality, 
tumor size, tumor extension, number of nodes examined, 
number of nodes positive, TNM stages, Mets at diagnosis, 
type of surgery, cause of death, vital status, and survival 
months.
Statistical­analysis
Chi- square and t- tests compared differences between the 
ethnic groups with respect to treatment and patient/tumor 
characteristics. Cox proportional hazards models 
(Therneau, Grambsch) [8] were used to calculate adjusted 
hazard ratios with their 95% confidence intervals and to 
show how treatment and other covariates were related to 
overall survival OS and LCSS. Medicare eligibility was 
controlled through use of two strata for age at diagnosis 
(≥65 years old vs. <65 years) because individual cases 
will change when they enroll in Medicare.
Results
Median follow- up time was calculated by the methods of 
Schemper and Smith in which death becomes a censored 
1213© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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follow- up time and was noted to be 35 and 31 months 
in the TP and Stage IV groups, respectively [9].
Complete demographic and histologic details of the TP 
(153,027) and Stage IV (70,968) populations can be seen 
in Table 1. Median age in the TP and Stage IV are 68.0 
and 67.0, respectively. There was a male predominance 
to both populations (54.1%- TP, and 55.8%- Stage IV). 
The three largest ethnic groups in the TP and Stage IV 
population were White, Black, and Hispanic and were 
74.4%, 12.3%, and 5.7%; and 72.3%, 13.2%, and 6.3%, 
respectively. A similar proportion of the Stage IV (31.7%) 
and TP (32.3%) patients presented with a low median 
family income (<$50,000). The majority were married 
with 51.6% and 51.2% in the TP and Stage IV, respec-
tively. 82.3% and 80.1% of TP and Stage IV patients 
All Patients (TP) 
N = 153,027
Stage IV patient 
N = 70,968
Uninsured 5272 (3.4%) 3145 (4.4%)
Unknown 1138 (0.74%) 640 (0.96%)
Lateral location
Bronchus, Left 2427 (1.6%) 1311 (1.8%)
Bronchus, Right 2427 (2.2%) 1875 (2.6%)
Bronchus, Unknown 168 (0.11%) 103 (0.15%)
Left Lower 17,384 (11.4%) 7266 (10.2%)
Left Upper 35,216 (23.0%) 14,827 (20.9%)
Left NOS 4733 (3.1%) 2993 (4.2%)
Lung, NOS 6207 (4.1%) 5382 (7.6%)
Left Overlapping 507 (0.32%) 249 (0.35%)
Right Lower 22,457 (14.7%) 9476 (13.4%)
Right Middle 6376 (4.2%) 2848 (4.0%)
Right Upper 45,478 (29.7%) 19,134 (27.0%)
Right NOS 7460 (4.9%) 4921 (6.9%)
Right Overlapping 1268 (0.83%) 583 (0.82%)
Histology—No. (%)
Adenocarcinoma 80,499 (52.6%) 39,415 (55.5%)
Squamous Cell Ca 41,573 (27.2%) 14,239 (20.0%)
Non- small- cell Ca, NOS 22,886 (15.0%) 13,603 (19.2%)
Large Cell Ca 4519 (3.0%) 2301 (3.2%)
Adenosquamous Cell Ca 2442 (1.6%) 921 (1.3%)
Others 1108 (0.72%) 489 (0.69%)
Grade
Well, I 8365 (5.4%) 1795 (2.5%)
Moderately, II 30,010 (19.6%) 7974 (11.2%)
Poorly, III 45,364 (29.6%) 19,445 (27.3%)
Undifferentiated, IV 2497 (1.6%) 1142 (1.6%)
Unknown 66,791 (43.8%) 40,612 (57.2%)
Definitive surgical procedure 39,105 (25.6%)
Radiation given 64,552 (41.8%) 33,689 (47.5%)
Year of diagnosis
2007 25,396 (16.6%) 11,589 (16.3%)
2008 25,529 (16.7%) 11,572 (16.3%)
2009 25,650 (16.8%) 11,848 (16.7%)
2010 25,631 (16.7%) 12,135 (17.1%)
2011 25,459 (16.6%) 11,807 (16.6%)
2012 25,362 (16.6%) 12,017 (16.9%)
Table 1. (continued)Table 1. Demographic characteristics of both the TP and Stage IV 
patients.
All Patients (TP) 
N = 153,027
Stage IV patient 
N = 70,968
Age—year, median 68.0 67.0
Sex
Female 70,212 (45.9%) 31,353 (44.2%)
Male 82,815 (54.1%) 39,615 (55.8%)
Race
White Hispanic 8579 (5.6%) 4441 (6.3%)
White non- Hispanic 114,013 (74.5%) 51,296 (72.3%)
Black 18,852 (12.3%) 9360 (13.2%)
Chinese 2413 (1.6%) 1261 (1.8%)
Japanese 1229 (0.80%) 567 (0.80%)
South Asian 451 (0.29%) 238 (0.34%)
Other Asians 4831 (3.2%) 2544 (3.6%)
Other Races 1957 (1.3%) 943 (1.3%)
American Indian/Alaskan 
Native
702 (0.46%) 318 (0.45%)
SEER registry
Alaska Natives 199 (0.13%) 76 (0.11%)
Atlanta 4629 (3.0%) 2226 (3.1%)
California excl SF/SJM/LA 30,007 (19.6%) 14,304 (20.2%)
Connecticut 8088 (5.30%) 3639 (5.1%)
Detroit 9852 (6.4%) 4632 (6.5%)
Greater Georgia 14,260 (9.3%) 6380 (9.0%)
Hawaii 2375 (1.6%) 1159 (1.6%)
Iowa 6805 (4.4%) 3205 (4.5%)
Kentucky 13,916 (9.1%) 5980 (8.4%)
Los Angeles 11,437 (7.5%) 5789 (8.2%)
Louisiana 10,783 (7.0%) 4767 (6.7%)
New Jersey 17,451 (11.4%) 7796 (11.0%)
New Mexico 2610 (1.7%) 1215 (1.7%)
Rural Georgia 353 (0.23%) 140 (0.20%)
San Francisco–Oakland 7081 (4.6%) 3469 (4.9%)
San Jose–Monterey 3203 (2.1%) 1635 (2.3%)
Seattle 8271 (5.4%) 3726 (5.3%)
Utah 1707 (1.1%) 830 (1.2%)
Income
<$50,000 49,407 (32.3%) 22,524 (31.7%)
$50,000–74,000 81,027 (52.9%) 37,933 (53.5%)
≥75,000 22,593 (14.8%) 10,511 (14.8%)
Marital status
Divorced 18,851 (12.3%) 8815 (12.4%)
Married 78,957 (51.6%) 36,349 (51.2%)
Separated 1785 (1.2%) 895 (1.3%)
Single 21,126 (13.8%) 10,872 (15.3%)
Unknown 6032 (3.9%) 2866 (4.0%)
Domestic Partner 126 (0.082%) 60 (0.084%)
Widowed 26,150 (17.1%) 11,111 (15.7%)
Tumor stage
Unknown 3174 (2.0%) 0
I 34,255 (22.3%) 0
II 7825 (5.1%) 0
III 39,979 (26.1%) 0
IV 70,968 (46.3%) 70,968 (100.0%)
Insurance
Insured 125,876 (82.3%) 56,859 (80.1%)
Medicaid 20,741 (13.6%) 10,324 (14.5%)
(continues)
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were insured. Adenocarcinoma was the predominant his-
tology in both populations (52.6%, TP; and 55.5%, Stage 
IV).
Table S1 supplemental contains the unadjusted demo-
graphic, histologic, and treatment details in the TP and 
used Whites as the reference group. Blacks were presented 
with younger age, more males, lower median household 
income, more uninsured, higher stages, lower percentage 
of squamous cell carcinomas, lower rates of definitive 
surgery, and lower OS/LCSS. Hispanics were presented 
at a younger age, higher median household income, more 
uninsured, higher percentage of metastatic disease, higher 
percentage of adenocarcinomas, and lower rates of defini-
tive surgery, but had a similar OS/LCSS. The Japanese 
were presented with a highest mean age (72.8), the only 
female predominance (51.2%), and the highest rates of 
insurance (96.4%), but there were a similar OS and LCSS 
compared to Whites. Whites were presented with the 
higher percentage of Stage I disease (23.4%) than all except 
for the South Asian and AI/AN. South Asians were pre-
sented with the highest percentage of metastatic disease 
at 52.8%. The Chinese were presented with the highest 
Figure 1. (A) Unadjusted overall survival by ethnic group in the total population. (B) Multivariable- adjusted overall survival by ethnic group in the total 
population.
Unadjusted overall survival
By race of patient
N = 153,027
P<0.001
South Asian
Other Asian
White Hispanic
American Indian/Alaskan Native
Japanese
White Non-Hispanic
Other Race ChineseBlack
Multivariable-adjusted overall survival
By race of patient
N = 153,027
P<0.001
American Indian/Alaskan Native
White Hispanic
Chinese South Asian
Japanese
White Non-Hispanic
Black
Other Race
Other Asian
(a)
(b)
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percentage of adenocarcinomas (69.4%), while AI/AN were 
presented with the highest percentage of squamous cell 
carcinomas (30.8%). Whites had significantly higher rates 
of definitive surgical procedures except for the Chinese, 
Japanese, and South Asians. As compared to the White 
population, OS and LCSS were significantly greater in 
the Chinese, South Asians, other Asians, and other racial 
groups. Blacks had a lower OS and LCSS. Unadjusted 
OS by ethnic group can be found in Figure 1A.
Multivariable analyses for OS and MVA- adjusted OS 
in the TP can be seen in Table 2 and Figure 1B. Advancing 
age (P < 0.0001, HR = 1.185) and male sex (P < 0.0001, 
HR = 1.245) were associated with worse OS. Whites had 
a lower OS than all races (HR = 0.705–0.977) except for 
AI/AN who had a similar OS (P = 0.4890, HR = 0.963). 
OS was lower for lower (P = 0.0097, HR = 1.024) and 
better for higher median household incomes (P < 0.001, 
Table 2. Multivariate analysis for OS in TP, N = 153,207.
All (N = 153,207) P- value
Hazard 
ratio
Age—year 1.185 <0.0001
Sex
Female – 1.0
Male <0.0001 1.245
Race
White non- Hispanic – 1.0
White Hispanic <0.0001 0.937
Black 0.0205 0.977
Chinese <0.0001 0.705
Japanese 0.0061 0.903
South Asian <0.0001 0.733
Other Asians <0.0001 0.762
Other Races <0.0001 0.792
American Indian/Alaskan Native 0.4890 0.963
SEER Registry
Alaska Natives 0.3002 1.111
Atlanta 0.1724 1.032
California excl SF/SJM/LA 0.0003 1.060
Connecticut – 1.0
Detroit 0.3908 1.017
Greater Georgia <0.0001 1.095
Hawaii <0.0001 1.149
Iowa 0.0002 1.081
Kentucky <0.0001 1.135
Los Angeles 0.3514 0.983
Louisiana <0.0001 1.141
New Jersey 0.0117 1.044
New Mexico 0.6428 1.014
Rural Georgia 0.9719 0.998
San Francisco–Oakland 0.0325 1.046
San Jose–Monterey 0.1455 1.040
Seattle 0.2381 1.024
Utah 0.0011 1.114
Income
<$50,000 0.0097 1.024
$50,000–74,000 – 1.0
≥75,000 <0.0001 0.936
Insurance
Insured 1.0
Medicaid <0.0001 1.200
Uninsured <0.0001 1.246
Unknown <0.0001 1.197
Marital status
Married – 1.0
Divorced <0.0001 1.144
Separated 0.0001 1.120
Single <0.0001 1.166
Unknown 0.0004 1.062
Domestic Partner 0.3785 1.124
Widowed <0.0001 1.147
Tumor stage
I – 1.0
II <0.0001 1.622
III <0.0001 1.994
IV <0.0001 3.290
(continues)
All (N = 153,207) P- value
Hazard 
ratio
Lateral location
Right upper – 1.0
Bronchus, Left <0.0001 1.232
Bronchus, Right <0.0001 1.297
Bronchus, Unknown 0.0169 1.226
Left Lower <0.0001 1.062
Left Upper 0.0874 1.015
Left NOS <0.0001 1.228
Lung, NOS <0.0001 1.211
Left Overlapping 0.0077 1.152
Right Lower <0.0001 1.083
Right Middle 0.2052 1.022
Right NOS <0.0001 1.253
Right Overlapping <0.0001 1.313
Histology—No. (%)
Adenocarcinoma – 1.0
Adenosquamous <0.0001 1.196
Large Cell <0.0001 1.176
Nonsmall Cell <0.0001 1.149
Others <0.0001 1.536
Squamous <0.0001 1.113
Grade
Well, I – 1.0
Moderately, II <0.0001 1.372
Poorly, III <0.0001 1.629
Undifferentiated, IV <0.0001 1.731
Unknown <0.0001 1.537
Definitive Surgical Procedure <0.0001 0.331
Radiation <0.0001 0.759
Year of diagnosis
2007 – 1.0
2008 0.0664 0.982
2009 0.0002 0.963
2010 <0.0001 0.956
2011 <0.0001 0.914
2012 <0.0001 0.891
Table 2. (continued)
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HR = 0.936). Insured patients had a better OS than the 
uninsured, those on Medicaid and those with unknown 
insurance (all P < 0.0001, HR = 1.197–1.246). Married 
patients had a better OS than separated, single, widowed, 
and unknown (all P ≤ 0.0004, HR = 1.062–1.166). As 
compared to Stage I, Stages II- IV had a worse OS with 
increasing HRs with stage (all P < 0.0001, HR = 1.622–
3.290). The lower lobes and mainstem bronchi locations 
were associated with worse OS. All histologies had a worse 
OS (all P < 0.0001, HR = 1.113–1.536) than adenocar-
cinomas. Compared to well- differentiated tumors, other 
tumor grades had worse OS (all P < 0.0001, HR = 1.372–
1.731). Patients who received radiation (P < 0.0001, 
HR = 0.759) or definitive surgery (P < 0.0001, HR = 0.331) 
had a better OS. OS by insurance, income, and marital 
status for TP can be seen in Figure 2A–C.
Multivariable analyses for OS for the Stage IV popula-
tion can be seen in Table 3. Age (P < 0.0001, HR = 1.017) 
and male sex (P < 0.0001, HR = 1.233) were associated 
with worse OS. All races had better OS than Whites 
(HR = 0.709–0.898) except for AI/AN and Blacks who 
had a similar OS. OS decreased for lower incomes 
(P = 0.0484, HR = 1.025) and increased for higher incomes 
(P < 0.001, HR = 0.934). Insured patients had a better 
OS than uninsured and those with Medicaid and unknown 
insurance (all P < 0.0001, HR = 1.195–1.277). Married 
patients or those with a domestic partner had better OS 
than those not living in a stable partner situation (divorced, 
P < 0.0001, HR = 1.154; widowed, P < 0.0001, HR = 1.149; 
separated, P = 0.0009, HR = 1.134; and unknown, 
P = 0.0023, HR = 1.069). Involvement of mainstem bron-
chi and right lower lobe was deleterious for OS. All other 
histologies were associated with a worse OS compared to 
adenosquamous cell carcinoma or adenocarcinoma (all 
P < 0.0001, HR = 1.107–1.482). All tumors differentiation 
compared to well- differentiated had significantly worse OS 
(all P < 0.0001, HRs 1.258–1.702). Palliative radiation 
significantly improved OS (P < 0.0001, HRs 0.896). Starting 
in the year 2010, OS started to significantly improve with 
progressively lower HRs each year.
Discussion
A major finding of our analysis is Blacks often present 
at a younger age, have worse prognostic characteristics, 
and a lower OS/LCSS than Whites. However, after mul-
tivariable adjustment, Blacks have a better OS in the TP 
and similar OS in the Stage IV patients as compared to 
Whites. Blacks present with many poor prognostic factors 
including the following: lower median household income, 
single/widowed partnership status, higher male predomi-
nance, more uninsured, higher stages, and lower rates of 
definitive surgery. However, Blacks did present at a younger 
age and have a lower percentage of squamous cell car-
cinomas, both of which are associated with a better prog-
nosis. As insurance, presentation stage, and surgical 
eligibility can be altered, there is hope that outcomes for 
Blacks can be improved with better access to insurance 
and by increased CT screening [10]. In comparison with 
Figure 2. Multivariable- adjusted overall survival in the total population. 
(A) by insurance; (B) by income; (C) by marital status.
Multivariable-adjusted overall survival
By type of insurance
N = 153,027
P<0.001
Insured
Unknown
Medicaid
Uninsured
Multivariable-adjusted overall survival
By median household income
N = 153,027
P<0.001
50K-74K
≥75K
<50K
Multivariable-adjusted overall survival
By marital status
N = 153,027
P<0.001
Married
Divorced
Unknown Separated
Widowed
Single
(a)
(b)
(c)
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Whites, Hispanics presented with a higher proportion of 
several risk factors associated with poor prognosis includ-
ing more uninsured, a lower proportion of Stage I/II 
tumors, and lower rates of definitive surgery, but there 
was no detrimental effect on the unadjusted OS or LCSS 
in the TP. Furthermore, MVAs demonstrated OS was 
significantly better for Hispanics compared to Whites in 
both the TP and Stage IV populations. It should be noted 
that previous analysis demonstrated this preferential OS 
benefit associated with Hispanics may be limited to those 
who are foreign- born as compared to those born in the 
United States [11]. Because the East Asian populations 
are enriched for the EGFR mutation tumors [12], it is 
not surprising the Chinese, South Asian, other Asians, 
and Japanese had a better adjusted OS in the TP/Stage 
IV populations, although this analysis lacks details on the 
mutational status of tumors.
In both MVAs for OS in the TP and Stage IV popula-
tions, male sex, poorer tumor differentiation, higher tumor 
stage, and advanced age were shown to be poor prognostic 
features and have been well established [13, 14]. 
Furthermore, palliative radiation therapy was found to 
be important for OS in the Stage IV population. 
All (n = 70,968) P- value Hazard ratio
Left NOS <0.0001 1.181
Lung, NOS <0.0001 1.214
Left Overlapping 0.0241 1.168
Right Lower 0.0037 1.041
Right Middle 0.4196 0.982
Right NOS <0.0001 1.163
Right Overlapping 0.0002 1.186
Histology—No. (%)
Adenocarcinoma – 1.0
Adenosquamous 0.0831 1.067
Large Cell <0.0001 1.174
Nonsmall Cell <0.0001 1.186
Others <0.0001 1.482
Squamous <0.0001 1.107
Grade
Well, I
Moderately, II <0.0001 1.258
Poorly, III <0.0001 1.627
Undifferentiated, IV <0.0001 1.702
Unknown <0.0001 1.645
Radiation <0.0001 0.896
Number of Nodes examined
Year of Diagnosis
2007 – 1.0
2008 0.4704 0.990
2009 0.0684 0.976
2010 0.0332 0.971
2011 <0.0001 0.937
2012 <0.0001 0.899
Table 3. (continued)Table 3. Multivariate Analysis for OS in Stage IV population, N = 70,968.
All (n = 70,968) P- value Hazard ratio
Age—year <0.0001 1.017
Sex
Female – 1.0
Male <0.0001 1.233
Race
White non- Hispanic – 1.0
White Hispanic <0.0001 0.924
Black 0.1704 0.982
Chinese <0.0001 0.709
Japanese 0.0281 0.898
South Asian <0.0001 0.729
Other Asians <0.0001 0.776
Other Races <0.0001 0.800
American Indian/Alaskan Native 0.9669 0.997
SEER Registry
Alaska Natives 0.3708 1.136
Atlanta 0.6764 0.987
California excl SF/SJM/LA 0.2900 1.022
Connecticut – 1.0
Detroit 0.7774 1.007
Greater Georgia 0.0971 1.042
Hawaii 0.0229 1.097
Iowa 0.0442 1.057
Kentucky 0.0487 1.052
Los Angeles 0.0346 0.950
Louisiana 0.0044 1.078
New Jersey 0.9390 0.998
New Mexico 0.9163 1.004
Rural Georgia 0.9052 1.011
San Francisco–Oakland 0.5813 1.015
San Jose–Monterey 0.4499 0.975
Seattle 0.9550 1.001
Utah 0.6367 1.020
Income
<$50,000 0.0484 1.025
$50,000–74,000 – 1.0
≥75,000 <0.0001 0.934
Insurance
Insured – 1.0
Medicaid <0.0001 1.195
Uninsured <0.0001 1.273
Unknown <0.0001 1.277
Marital status
Married – 1.0
Divorced <0.0001 1.154
Separated 0.0009 1.134
Single <0.0001 1.167
Unknown 0.0023 1.069
Domestic Partner 0.1157 1.283
Widowed <0.0001 1.149
Lateral location
Right upper – 1.0
Bronchus, Left <0.0001 1.210
Bronchus, Right <0.0001 1.330
Bronchus, Unknown 0.0104 1.308
Left Lower 0.0607 1.029
Left Upper 0.5952 1.006
(continues)
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Involvement of the mainstem bronchi and lower lobes 
was associated with worse OS. Although it can be hypoth-
esized the involvement of the mainstem bronchi can 
contribute to an increased mortality due to postobstructive 
pneumonia and/or hypoxia, the survival decrement noted 
with the lower lobe locations may be due to a greater 
involvement of normal lung volumes. Because of the 
known ability of radiation to alleviate symptoms in Stage 
IV lung cancer [15], we feel the OS benefit noted with 
radiation in this study may be due to its palliation of 
central- based obstructive masses.
Since 2010 (2009 in TP), a consistent improvement in 
OS was noted in both populations. Although our analysis 
is unable to identify reasons for this progressive improve-
ment, we feel the reasons are multifactorial. We speculate 
better staging with frequent use of CT/PET scanning [16] 
is associated with better outcomes. However, the benefits 
in the Stage IV population may have also been due to 
the recognition of chemotherapeutic regimens based upon 
histology [17] and benefits of targeted therapeutic agents 
for EGFR mutations [18] and EML4- ALK translocations 
[19]. Unfortunately, SEER does not contain information 
regarding the mutations or systemic therapy.
In both patient populations, MVA demonstrated higher 
income was positively associated with OS. Lower socio-
economic status was previously shown to affect cancer 
mortality and to be associated with modifiable risk factors 
such as smoking, diet, BMI, and lower levels of physical 
activity [20]. Unfortunately, these modifiable risk factors 
are not contained within SEER- 18, but information con-
cerning insurance is available and is more strongly cor-
related with OS than income. Furthermore, cigarette 
smoking is noted to be more prevalent in lower socio-
economic groups [21] and could account for the lower 
OS associated with economic factors. The effects of not 
being insured have greater effect on OS not only in this 
population group, but in our companion article concern-
ing surgical patients in these same ethnic groups. It is 
interesting to note patients with Medicaid have similar 
hazard ratios for adverse outcomes as compared to those 
without insurance. We hypothesize the poor outcomes 
noted in the Medicaid population may be due to the 
socioeconomic conditions of individuals who have this 
coverage or possibly due to provider differences. Similar 
poor outcomes of patients who are receiving Medicaid 
or who are uninsured have recently been reported in 
patients with testicular cancers, glioblastomas, and head 
and neck cancers [22–24]. Nevertheless, hopefully, Medicaid 
expansion will provide better health outcomes for patients 
with cancer and has already been associated with increases 
in medication adherence, preventive care, and healthcare 
quality [25]. In a database of 75 countries obtained from 
the World Bank and WHO (1990–2010), unemployment 
was associated with increased lung cancer mortality, but 
only in men [26]. The effects of unemployment on cancer 
mortality appeared to be mitigated by universal health 
coverage. Our results suggest the type of insurance can 
affect the prognosis of patients with short expected sur-
vivals, that is, Stage IV. Although higher lung cancer 
mortality was recently noted in the mid- South [27] and 
our analysis indicates there is worse OS in Kentucky and 
Louisiana in both patient populations, the effects of geog-
raphy on poor prognosis in our study were not limited 
to those areas. Our results show married patients or those 
with a domestic partner have a significantly longer survival, 
even in metastatic disease. Although our results conflict 
with those of a past investigation [28] in patients with 
lung cancer, other investigators have noted unmarried 
patients with lung cancer had a greater incidence of depres-
sion, less social support, and a survival decrement [29].
SEER- 18 lacks many variables including smoking, diet, 
BMI, levels of physical activity, type of chemotherapeutic 
agents, radiation doses/volumes, surgical complications, 
medical office visits, and patient comorbidities. Therefore, 
our analysis cannot account for these variables.
It should be noted that there are past studies that 
have shown that Blacks have uniformly worse outcomes 
than Whites [30–33], our study is more comprehensive 
in that we assess nine different ethnic groups and because 
we adjust for marital, economic, histopathologic, and 
insurance variables. Our comprehensive analysis allows 
for a unique finding that Blacks may have better (TP) 
or similar (Stage IV) outcomes as compared to the White 
population. Therefore, because the White Hispanic and 
Black populations present at more advanced stages and 
have better outcomes, we feel that increased lung cancer 
screening would be preferentially better in these patients. 
Such a clear pathway for survival improvement in the 
White population cannot be ascertained in our popula-
tion. Unfortunately, SEER does not contain genomic 
information by race or otherwise. However, at present, 
genomic information in patients with lung cancer is 
not prevalent enough (5% or 10% frequency) in ethnic 
groups other than Whites in the Cancer Genome Atlas 
(TCGA) [34].
Conclusion
In summary, our analysis does demonstrate racial dispari-
ties do exist in the presentation of the Black and Hispanic 
populations with lung cancer. Both groups were presented 
with lower rates of insurance, higher stages, and lower 
rates of definitive surgery. Blacks had a lower OS/LCSS, 
but when adjusted for histopathologic, therapeutic, marital 
status, and economic factors, they had a better OS in 
the TP than Whites. Disparities in income, marital status, 
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and insurance rather than ethnicity affect OS of patients 
with lung cancer. Because of their more common pres-
entation with advanced disease, the Black and Hispanic 
groups may benefit preferentially from screening. Our 
analyses support the expansion of lung cancer screening 
to people at higher risk of presenting with advanced stage 
secondary to limited access to health care due to lower 
income and lack of insurance, particularly in the Black 
and Hispanic groups. Specifically, affordable and quality 
healthcare needs to be provided to these at- risk popula-
tions possibly by education/health literacy and care navi-
gators/coordinators. However, the outcome improvement 
in the White population may need attention in areas other 
than just screening.
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